Gedea Biotech develops pHyph, an antibiotic free and effective treatment of vaginal infections. Vaginal infections affect at least 400 million women every year worldwide and the market is worth over $ 1.5 billion. 67% of women with a vaginal infection choose an ineffective treatment because they do not know if it is a fungal or bacterial infection. pHyph will be the only treatment on the market targeting both bacterial and fungal vaginal infections, reducing the risk of choosing the wrong treatment. Gedea Biotech was founded in 2015 in Lund, Sweden.